These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7116653)

  • 1. Reduced dopaminergic inhibition of thyrotrophin release in states of physiological hyperprolactinaemia.
    Rodriguez-Arnao MD; Weightman DR; Hall R; Scanlon MF; Camporro JM; Gomez-Pan A
    Clin Endocrinol (Oxf); 1982 Jul; 17(1):15-9. PubMed ID: 7116653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function.
    Scanlon MF; Rodriguez-Arnao MD; McGregor AM; Weightman D; Lewis M; Cook DB; Gomez-Pan A; Hall R
    Clin Endocrinol (Oxf); 1981 Feb; 14(2):133-43. PubMed ID: 6790201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interrelationships between prolactin and thyrotrophin secretion following dopaminergic blockage in patients with mild hyperprolactinaemia without any demonstrable pituitary tumour.
    Spitz IM; Haas M; Trestian S; Zylber-Haran E; Shilo S
    Clin Endocrinol (Oxf); 1983 Sep; 19(3):285-94. PubMed ID: 6414745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocal pattern of the TSH and PRL responses to dopamine receptor blockade in women with physiological or pathological hyperprolactinaemia.
    Massara F; Camanni F; Martra M; Dolfin GC; Müller EE; Molinatti GM
    Clin Endocrinol (Oxf); 1983 Feb; 18(2):103-10. PubMed ID: 6851194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a dopamine antagonist (metoclopramide) on the release of the adenohypophyseal hormones in amenorrhoeic patients with and without hyperprolactinaemia.
    Seki K; Uesato T; Kato K
    Acta Endocrinol (Copenh); 1982 Oct; 101(2):166-70. PubMed ID: 6814135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced hypothalamic dopaminergic inhibition of LH, TSH and GH release in patients with pathological hyperprolactinaemia.
    Ho KY; Smythe GA; Lazarus L
    Acta Endocrinol (Copenh); 1985 Mar; 108(3):289-96. PubMed ID: 3984660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery.
    Scanlon MF; Peters JR; Salvador J; Richards SH; John R; Howell S; Williams ED; Thomas JP; Hall R
    Clin Endocrinol (Oxf); 1986 Apr; 24(4):435-46. PubMed ID: 3091297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactin-secreting pituitary adenomas: prolactin dynamics before and after transsphenoidal surgery.
    Barbarino A; de Marinis L; Menini E; Anile C; Maira G
    Acta Endocrinol (Copenh); 1979 Jul; 91(3):397-409. PubMed ID: 112818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect.
    Rodriguez-Arnao MD; Peters JR; Foord SM; Dieguez C; Edwards C; Gomez-Pan A; Hall R; Newcombe RG; Scanlon MF
    J Clin Endocrinol Metab; 1983 Nov; 57(5):975-80. PubMed ID: 6619271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone responsiveness to metoclopramide in hyperprolactinaemia.
    O'Malley BP; Mercey D; Clarke E; Maguire M; Jackson J; Rosenthal FD
    Clin Sci (Lond); 1987 Mar; 72(3):277-82. PubMed ID: 3816084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of altered dopaminergic modulation of Prl, LH, FSH, GH and TSH secretion during chronic partial dopamine receptor blockade in normal women.
    Hagen C; Andersen AN; Djursing H
    Acta Endocrinol (Copenh); 1984 May; 106(1):1-7. PubMed ID: 6428112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prl, TSH, GH and LH responses to metoclopramide and breast-feeding in normal and hyperprolactinaemic women.
    Andersen AN; Tabor A
    Acta Endocrinol (Copenh); 1982 Jun; 100(2):177-83. PubMed ID: 7202316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of subacute cabergoline treatment on prolactin, thyroid stimulating hormone and growth hormone response to simultaneous administration of thyrotrophin-releasing hormone and growth hormone-releasing hormone in hyperprolactinaemic women.
    Giusti M; Lomeo A; Torre R; Sghedoni D; Mazzocchi G; Durante R; Giordano G
    Clin Endocrinol (Oxf); 1989 Mar; 30(3):315-21. PubMed ID: 2574083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of altered dopaminergic modulation of Prl, LH and TSH secretion in patients with normoprolactinaemic amenorrhoea.
    Hagen C; Petersen K; Djursing H; Andersen AN
    Acta Endocrinol (Copenh); 1984 May; 106(1):8-14. PubMed ID: 6428118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactin and TSH responses to both domperidone and TRH in normal and hyperprolactinaemic women after dopamine synthesis blockade.
    Ghigo E; Goffi S; Molinatti GM; Camanni F; Massara F
    Clin Endocrinol (Oxf); 1985 Aug; 23(2):155-60. PubMed ID: 3931942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients.
    De Marinis L; Mancini A; Minnielli S; Masala R; Anile C; Maira G; Barbarino A
    Metabolism; 1985 Oct; 34(10):917-22. PubMed ID: 4046835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased dopaminergic activity inhibits basal and metoclopramide-stimulated prolactin and thyrotropin secretion.
    Agner T; Hagen C; Andersen AN; Djursing H
    J Clin Endocrinol Metab; 1986 Apr; 62(4):778-82. PubMed ID: 3949956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid function in patients with hyperprolactinaemia: relationship to dopaminergic inhibition of TSH release.
    Dieguez C; Peters JR; Page MD; John R; Hall R; Scanlon MF
    Clin Endocrinol (Oxf); 1986 Oct; 25(4):435-40. PubMed ID: 3621619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of dopaminergic inhibition on serum levels of thyrotrophin and prolactin in patients with hypothyroidism before and after prolonged oral administration of TRH.
    Frey HM; Haug E
    Acta Endocrinol (Copenh); 1983 Oct; 104(2):183-8. PubMed ID: 6415988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The TSH response to domperidone reflects the biological activity of prolactin in macroprolactinaemia and hyperprolactinaemia.
    Pinto LP; Hanna FW; Evans LM; Davies JS; John R; Scanlon MF
    Clin Endocrinol (Oxf); 2003 Nov; 59(5):580-4. PubMed ID: 14616880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.